

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31st MARCH 2014

Part I Particulars	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Three months ended			Nine months ended		Year ended
	Mar 31,	Dec 31,	Mar 31,	Mar 31,	Mar 31,	June 30,
	2014	2013	2013	2014	2013	2013
	Rs. In Lakhs					Rs. In Lakhs
1 Income						
a. Net Sales/ income from operations (Net of Excise Duty)	3,832.48	3,866.94	2,796.77	11,526.04	8,426.04	11,878.17
b. Foreign Exchange Fluctuation Gain	146.74	2.60	10.91	-	181.28	-
c. Share of profits in LLP	159.48	215.82	103.70	524.54	248.01	389.05
d. Total	4,138.70	4,085.36	2,911.38	12,050.58	8,855.33	12,267.22
2 Expenditure						
a. Cost of materials consumed	516.51	523.05	708.80	1,828.71	2,251.65	3,064.80
b. Purchase of Stock-in-Trade	1,895.78	1,873.93	1,214.09	5,559.59	3,723.23	5,273.34
c. Change in inventories of Finished Goods, work in progress and stock in trade	8.12	110.30	35.54	5.83	(87.93)	(106.97)
d. Employees benefit expenses	332.86	289.48	190.64	887.78	524.74	750.39
e. Depreciation	86.46	51.08	34.77	180.45	100.14	143.77
f. Amortisation of Intangible Assets	1.90	1.20	0.27	5.40	0.81	1.55
g. Foreign Exchange Fluctuation Loss	-	-	-	311.54	-	218.66
h. Research and Development Expenses	42.95	23.98	16.31	92.72	54.99	65.76
i. Other Expenditure	348.27	326.30	207.32	926.76	605.19	847.36
j. Total	3,232.85	3,199.32	2,407.74	9,798.78	7,172.82	10,258.66
3 Profit(+)/Loss(-) from Operations before other income and finance cost and exceptional items (1-2)	905.85	886.04	503.64	2,251.80	1,682.51	2,008.56
4 Other Income	134.58	82.43	20.65	265.10	142.98	173.30
5 Profit(+)/Loss(-) from ordinary activities before finance cost and exceptional items (3+4)	1,040.43	968.47	524.29	2,516.90	1,825.49	2,181.86
6 Finance cost	1.52	1.53	2.54	6.59	14.91	30.06
7 Profit(+)/Loss(-) from Ordinary Activities after finance cost but before exceptional items (5-6)	1,038.91	966.94	521.75	2,510.31	1,810.58	2,151.80
8 Exceptional items	-	-	-	-	-	-
9 Profit(+)/Loss(-) from Ordinary Activities before Tax (7-8)	1,038.91	966.94	521.75	2,510.31	1,810.58	2,151.80
10 Provision for Taxation	145.00	135.00	115.00	390.00	400.00	475.00
Provision for Taxation - earlier years	-	-	-	-	-	8.56
Deferred Tax Provision	207.40	27.00	40.08	249.40	138.75	232.32
Mat Credit Entitlement	-	-	-	-	-	5.27
11 Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)	686.51	804.94	366.67	1,870.91	1,271.83	1,430.65
12 Extraordinary Item (net of tax expense)	-	-	-	-	-	-
13 Net Profit(+)/Loss(-) for the period (11-12)	686.51	804.94	366.67	1,870.91	1,271.83	1,430.65
14 Paid up Equity Share Capital (Face value of the share - Rs 10/- each)	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00
15 Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	2,505.35
16 Earnings/(Loss) Per Share (EPS) (Not annualised)						
(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	4.54	5.33	2.43	12.38	8.42	9.47
(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	4.54	5.33	2.43	12.38	8.42	9.47



	Part II	Select information for the Quarter ended 31st March 2014					
		Three months ended			Nine months ended		Year ended
		Unaudited	Unaudited	Unaudited	Unaudited		Audited
		Mar 31, 2014	Dec 31, 2013	Mar 31, 2013	Mar 31, 2014		June 30, 2013
A	PARTICULARS OF SHARE HOLDING						
17	Public Shareholding						
	- Number of Shares	6,239,247	6,470,647	6,470,647	6,239,247	6,470,647	6,470,647
	- Percentage of Shareholding	41.29%	42.82%	42.82%	41.29%	42.82%	42.82%
18	Promoters and promoter group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	8,870,753	8,639,353	8,639,353	8,870,753	8,639,353	8,639,353
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	58.71%	57.18%	57.18%	58.71%	57.18%	57.18%

B	Particulars	3 months ended 31-03-2014
	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	0
	Received during the quarter	28
	Disposed of during the quarter	28
	Remaining unresolved at the end of the quarter	Nil

Notes :

- 1) The Company operates in one segment only.
- 2) The above consolidated unaudited financial results were considered and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 12.05.2014
- 3) The Statutory Auditors have carried out a limited review of the results for the quarter ended 31st March, 2014.
- 4) The Consolidated financial results include the financial results of Argus Salud Pharma LLP in which controlling interest is held by the Company.
- 5) Prior year / period figures are regrouped / rearranged wherever necessary.

Place : Chennai
Dated : 12.05.2014


M. Jayapal
Managing Director



CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st MARCH 2014

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, Email ID-info@caplinpoint.net

Part I						
Particulars	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Three months ended			Nine months ended		Year ended
	Mar 31, 2014	Dec 31, 2013	Mar 31, 2013	Mar 31, 2014	Mar 31, 2013	June 30, 2013
	Rs. In Lakhs					Rs. In Lakhs
1 Income						
a. Net Sales/ income from operations (Net of Excise Duty)	4,140.31	4,279.69	2,886.71	12,513.18	8,790.37	12,702.83
b. Foreign Exchange Fluctuation Gain	158.30	5.44	10.56	-	176.87	-
c. Total	4,298.61	4,285.13	2,897.27	12,513.18	8,967.24	12,702.83
2 Expenditure						
a. Cost of materials consumed	744.57	779.92	833.87	2,480.21	2,566.71	3,530.90
b. Purchase of Stock-in-Trade	1,714.28	1,722.91	1,117.58	5,053.03	3,477.37	5,038.48
c. Change in inventories of Finished Goods, work in progress and stock in trade	(18.80)	146.90	(34.05)	25.80	(157.67)	(124.26)
d. Employees benefit expenses	341.44	298.60	196.59	915.62	544.62	780.83
e. Depreciation	89.07	53.53	36.96	187.85	106.51	152.47
f. Amortisation of Intangible Assets	1.90	1.20	0.27	5.40	0.81	1.55
g. Foreign Exchange Fluctuation Loss	-	-	-	310.91	-	254.53
h. Research and Development Expenses	42.95	23.98	16.31	92.72	54.99	65.76
i. Other Expenditure	389.27	356.80	234.76	1,034.90	685.90	968.33
j. Total	3,304.68	3,383.84	2,402.29	10,106.42	7,279.24	10,668.59
3 Profit(+)/Loss(-) from Operations before other income and finance cost and exceptional items (1-2)	993.94	901.28	494.99	2,406.76	1,688.00	2,034.24
4 Other Income	143.03	89.61	29.91	287.90	171.54	210.03
5 Profit(+)/Loss(-) from ordinary activities before finance cost and exceptional items (3+4)	1,136.97	990.89	524.90	2,694.65	1,859.54	2,244.27
6 Finance cost	1.62	1.64	2.58	6.92	14.96	30.24
7 Profit(+)/Loss(-) from Ordinary Activities after finance cost but before exceptional items (5-6)	1,135.35	989.25	522.32	2,687.73	1,844.58	2,214.03
8 Exceptional items	-	-	-	-	-	-
9 Profit(+)/Loss(-) from Ordinary Activities before Tax (7-8)	1,135.35	989.25	522.32	2,687.73	1,844.58	2,214.03
10 Provision for Taxation	216.40	180.00	142.50	546.40	459.50	565.74
Provision for Taxation - earlier years	-	-	-	-	-	8.56
Deferred Tax Provision	207.40	27.00	40.08	249.40	138.75	232.32
Mat Credit Entitlement	-	-	-	-	-	5.27
11 Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)	711.55	782.25	339.74	1,891.93	1,246.33	1,402.14
12 Extraordinary Item (net of tax expense)	-	-	-	-	-	-
13 Net Profit(+)/Loss(-) for the period before minority interest (11-12)	711.55	782.25	339.74	1,891.93	1,246.33	1,402.14
14 Minority Interest	1.61	2.18	1.05	5.30	2.51	3.76
15 Net Profit(+)/Loss(-) for the period after minority interest (13-14)	709.94	780.07	338.69	1,886.63	1,243.82	1,398.38
16 Paid up Equity Share Capital (Face value of the share - Rs 10/- each)	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00
17 Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	2,429.86
18 Earnings/(Loss) Per Share (EPS) (Not annualised)						
(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	4.70	5.16	2.24	12.49	8.23	9.25
(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	4.70	5.16	2.24	12.49	8.23	9.25



	Part II	Select information for the Quarter ended 31st March 2014					
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		Three months ended	Three months ended	Three months ended	Nine months ended	Nine months ended	Year ended
		Mar 31, 2014	Dec 31, 2013	Mar 31, 2013	Mar 31, 2014	Mar 31, 2013	June 30, 2013
A	PARTICULARS OF SHARE HOLDING						
19	Public Shareholding						
	- Number of Shares	6,239,247	6,470,647	6,470,647	6,239,247	6,470,647	6,470,647
	- Percentage of Shareholding	41.29%	42.82%	42.82%	41.29%	42.82%	42.82%
20	Promoters and promoter group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	8,870,753	8,639,353	8,639,353	8,870,753	8,639,353	8,639,353
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	58.71%	57.18%	57.18%	58.71%	57.18%	57.18%

B	Particulars	3 months ended 31-03-2014
	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	0
	Received during the quarter	28
	Disposed of during the quarter	28
	Remaining unresolved at the end of the quarter	Nil

Notes :

- 1) The Company operates in one segment only.
- 2) The above consolidated unaudited financial results were considered and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 12.05.2014
- 3) The Statutory Auditors have carried out a limited review of the results for the quarter ended 31st March, 2014.
- 4) The Consolidated financial results include the financial results of Argus Salud Pharma LLP in which controlling interest is held by the Company.
- 5) Prior year / period figures are regrouped / rearranged wherever necessary.

Place : Chennai
Dated : 12.05.2014


M. Jayapal
Managing Director





CNGSN & ASSOCIATES

CHARTERED ACCOUNTANTS

No. 43, (Old No. 22), Swathi Court, Flat No. C & D,
Vijayaraghava Road, T. Nagar, Chennai - 600 017
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

S. NEELAKANTAN
B.Com., FCA

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d

R. THIRUMALMARUGAN
M.Com., FCA

G. CHELLA KRISHNA
M.Com., FCA, PGPM

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

D. KALAIALAGAN
B.Com., FCA

V. VIVEK ANAND
B.Com., FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

K. PARTHASARATHY
B.Com., FCA

E.K. SRIVATSAN
B.Com., ACA

Limited Review on Unaudited Results

Review Report to

The Board of Directors,
Caplin Point Laboratories Limited
Chennai

We have reviewed the accompanying statement of unaudited financial results of CAPLIN POINT LABORATORIES LIMITED, Narbavi, No.3, Lakshmanan street, T.Nagar, Chennai – 600017, for the quarter ended 31st march, 2014 **except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us.** This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For CNGSN & ASSOCIATES
Chartered Accountants
Firm Reg. No. 4915 S

B.RAMAKRISHNAN
Partner
Membership No. 201023
Place: Chennai
Date: 09-05-2014



Offices at : • Chennai • Vellore • Puducherry • Hyderabad